AmpliPhi Biosciences Corp. (NYSE: APHB) Starts Presentation at LD Micro Main Event
AmpliPhi Biosciences (NYSE: APHB) is a clinical-stage biotechnology company focused on treating antibiotic-resistant infections using its proprietary bacteriophage-based technology. AmpliPhi’s lead product candidates target multidrug-resistant Staphylococcus aureus and Pseudomonas aeruginosa, which are included on the WHO’s 2017 Priority Pathogens List. Phage therapeutics are uniquely positioned to address the threat of antibiotic-resistance as they can be precisely targeted to kill select bacteria, have a differentiated mechanism of action, can penetrate and disrupt biofilms, are potentially synergistic with antibiotics and have been shown to restore antibiotic sensitivity to drug-resistant bacteria. For more information, visit the company’s website at www.ampliphibio.com. About NetworkNewsWire NetworkNewsWire…







